Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Phosphoseryl-tRNA kinase (PSTK) is a specialized enzyme essential for the biosynthesis of selenocysteine, the 21st amino acid, in eukaryotes and archaea [PubMed: 15145950]. It catalyzes the ATP-dependent phosphorylation of L-seryl-tRNA(Sec) to form O-phospho-L-seryl-tRNA(Sec), which is a mandatory intermediate for the subsequent conversion to selenocysteinyl-tRNA(Sec) by selenocysteine synthase [UniProt: Q8IV42]. This pathway is critical because selenocysteine is synthesized on its cognate tRNA rather than being loaded directly by an aminoacyl-tRNA synthetase. Selenoproteins, which incorporate this amino acid, play vital roles in antioxidant defense, thyroid hormone metabolism, and redox signaling [NCBI Gene: 118672]. While PSTK is not currently a primary target for approved drugs, its fundamental role in selenoprotein synthesis makes it a subject of interest in research regarding metabolic disorders and oxidative stress-related diseases [PubMed: 15145950].
Catalyzes the ATP-dependent phosphorylation of L-seryl-tRNA(Sec) to O-phospho-L-seryl-tRNA(Sec), which is a required intermediate for selenocysteine synthesis [UniProt: Q8IV42].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Phosphoseryl-tRNA kinase (PSTK).